Overview
Integrating Clinical Pharmacists Into Collaborative Care For Patients With T2D To Realize Early Benefits of Once-Weekly Insulin Regimens
Click the "Start Activity" button to indicate you have reviewed the CME/CE information for this activity.
Start Activity
The management of type 2 diabetes (T2D) is complex, requiring a multidisciplinary, patient-centered approach that accounts for individualized glycemic and weight goals, comorbidities, hypoglycemia risk, medication costs, and individual preferences. Therapeutic inertia and patient reluctance often delay insulin initiation and intensification in patients with persistent hyperglycemia despite multiple antihyperglycemic agents. The emergence of once-weekly basal insulin analogues represent a transformative advancement in T2D management, offering a simplified treatment paradigm to address common barriers to insulin initiation and adherence.
The novel pharmacokinetics, distinct initiation and titration protocols, and unique patient counseling requirements for once-weekly formulations present new educational challenges for the multidisciplinary diabetes care team. Clinical pharmacists integrated within the collaborative care team are well-positioned to counsel patients on medication use, identify cost-saving opportunities, and educate on proper insulin administration techniques.
To support translation and implementation of the latest evidence into routine clinical practice, this program provides pharmacists with a personalized learning experience. Pharmacists complete an initial assessment, receive individualized recommendations for education, and access tools and resources to develop their own action plan for keeping pace with the latest guidance and evidence to mitigate therapeutic inertia, individualize treatment, and optimize patient engagement when transitioning a T2D patient to a weekly basal insulin treatment plan.
This educational activity is designed for clinical pharmacists in hospital or ambulatory settings involved in the management of patients with T2D.
Upon completion of this activity, learners will be able to:
- Summarize guideline recommendations for the initiation and intensification of basal insulin therapy and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) in the management of type 2 diabetes mellitus (T2D)
- Describe the pharmacokinetic and pharmacodynamic profiles of once-weekly basal insulin analogues, including initiation strategies, titration protocols, and safety considerations
- Assess the latest clinical trial evidence surrounding the safety and efficacy of emerging once-weekly basal insulin therapies for T2D treatment
- Apply patient-centered approaches, including shared decision-making and diabetes self-management education and support (DSMES), to improve adherence and outcomes in individuals requiring insulin therapy
- Integrate continuous glucose monitoring (CGM) data and decision-support tools into clinical workflows to optimize insulin titration and reduce risk of hypoglycemia
- Evolving Landscape of Type 2 Diabetes (T2D) Management
- Once-Weekly Basal Insulin Analogues: Clinical Evidence and Implications
- Practical Considerations for Initiation, Switching, and Titration
- Role of Clinical Pharmacists Within Collaborative Practice Models to Mitigate Therapeutic Inertia and Optimize Persistence
- Mitigating Challenges and Implementation Strategies
Provided by the Academy for Continued Healthcare Learning (ACHL).
Supported by an educational grant from Lilly.
Athena Philis-Tsimikas, MD (Chair)
Corporate Vice President
Scripps Whittier Diabetes Institute
La Jolla, CA
Corporate Vice President
Scripps Whittier Diabetes Institute
La Jolla, CA
Kevin Cowart, PharmD, MPH, BCACP, CDCES
Associate Professor
Department of Pharmacotherapeutics & Clinical Research
USF Taneja College of Pharmacy
Tampa, FL
Jennifer Trujillo, PharmD
Professor, Department of Clinical Pharmacy
University of Colorado Anschutz
Skaggs School of Pharmacy
Aurora, CO
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in an accredited continuing education activity disclose all affiliations or other financial relationships within 24 months (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with all ineligible companies. All relevant financial relationships have been mitigated prior to this activity.
The following financial relationships have been provided:Athena Philis-Tsimikas, MD –
Grants/Research Support: Eli Lilly, Novo Nordisk
Kevin Cowart, PharmD, MPH, BCACP, CDCES –
Grants/Research Support: Sanofi Pharmaceuticals, Abbott Diabetes Care, ASHP Foundation
Jennifer Trujillo, PharmD –
No financial relationships to disclose
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of any ineligible company. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor(s).
This educational activity was planned and produced in accordance with the ACCME Standards for Integrity and Independence in Accredited Continuing Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity are based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation conforms to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Clinicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
Discussion of scientific information on unapproved uses (SIUU), off-label, investigational, or experimental drug/device use: Insulin efsitora alfa is not approved for use.
To receive credit, learners are required to complete a baseline assessment; design, develop, and implement an action plan using our automated platform; view online interventions; and return after 60 days to report progress in making system-level changes. A thorough response to the reflection questionnaire on your involvement in the quality improvement activity is also required for meaningful participation. A certificate will be available upon completion of the reflection questionnaire. There is no fee to participate in the activity or for the generation of the certificate.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
This activity has been approved for 3.5 contact hours.
ACPE Universal Activity Number: 0396-0000-26-005-H04-P
Activity Type: Application
Release Date: May 29, 2026
Expiration Date: May 29, 2027
